Shepard Jay sold (to issuer) 164,472 shares of ESPR
Shepard Jay sold (to issuer) 164,472 shares of Esperion Therapeutics, Inc. (ESPR) on 2026-07-13.
How this was made
The 30-second read
Why it matters
A director’s sale to the issuer can be interpreted as reduced insider exposure, but without price/value it is unlikely to change valuation expectations on its own.
Market read
Traders may monitor for follow-on insider activity or company buyback-related disclosures, but this filing alone is not a strong catalyst.
What to watch
Because the price and total value are not disclosed, the market may discount the signal; also, the absence of a 10b5-1 plan does not by itself indicate intent without additional context.
Background
The article is an SEC Form 4 insider transaction disclosure for Esperion Therapeutics, filed 2026-07-13.
Ticker impact
Esperion Therapeutics director Shepard Jay sold 164,472 shares to the issuer on 2026-07-13, with price undisclosed and holdings reduced to zero.
Likely limited near-term impact; any effect would be sentiment-driven and should fade unless followed by additional disclosures.
Form 4 shows a director sale with no 10b5-1 plan and zero shares after transaction, but the filing provides no transaction price or value, reducing tradable signal strength.
Market effects
No clear sector read-through from a single director sale without disclosed pricing or accompanying company news.
None.
None.
Counterpoint
The sale is to the issuer and may reflect planned liquidity or buyback mechanics rather than negative views on fundamentals.
Key entities
- issuerEsperion Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderShepard Jay
Director who sold 164,472 shares to the issuer and ended with 0 shares.